BIOQuébec Appoints a New Chairman of the Board

MONTREAL, Feb. 28, 2013 /CNW Telbec/ - BIOQuébec is pleased to announce the appointment of Dr. Martin Godbout as chairman of the Board, replacing Mr. Gilles R. Gagnon, who held this position during the last 2 years. Mr. Godbout's appointment comes into force today.

"Since its creation, BIOQuébec has played a key role as spokesperson of the biotechnology industry. It is with humility that I accept to collaborate, with all members of the Board, towards the development of strategies that will further the industry and promote the life sciences sector not only in Québec but abroad", stated Dr. Godbout.

As director on BIOQuébec's Board for the last 2 years, Dr. Godbout also sits on several other Boards of biotechnology companies, foundations and Canadian scientific organizations. He is president of the MethylGene inc. and Génome Québec Boards and acts as director on the Boards of the following organizations: Acasti Pharma Inc., AmorChem Inc., AngioChem Inc., AsmaCure Inc., BioContact, the Fonds de recherche du Québec - santé (FQRS), Montréal In Vivo and the Fondation de l'Ataxie de Charlevoix.

Dr. Godbout founded Génome Canada, and was its president and CEO for many years. Throughout his career, he sat on the Science and Technology Council of Québec and was a member of the Natural Sciences and Engineering Research Council of Canada. He also developed BioContact Québec, an annual symposium on biopharmaceutical partnerships. He held the position of senior vice-president of BioCapital, a major Canadian venture capital firm. Prior to this, he was CEO of Société Innovatech Québec, a technology investment fund. Dr. Godbout is an Officer of the Order of Canada and has received numerous awards in Canada and abroad.

BIOQuébec's Board of Directors would like to thank Mr. Gagnon for his contribution to the association and wishes him much luck in his future projects.

About BIOQuébec

BIOQuébec is a biotechnology and life science industry association representing nearly 100 member companies and R&D centres in Québec. The association works to create a positive business environment which fosters the growth of the life science industry, including access to capital and access to development and marketing partners, workforce development, a regulatory and competitive tax environment and the promotion of its members among various publics both in Québec and on an international level.

Board of Directors 2012-2013

  • Dr. Martin Godbout
    President of the Board
    Corporate Director
    Hodran Consultants Inc.
  • Mario Lebrun
    General Manager
  • Michel Fortin
    Prevtec microbia inc.
  • John-Michel T. Huss
    Corporate Director
  • Yves Roy
    Corealis Pharma Inc.
  • Andy Sheldon
    Medicago Inc.
  • Cédric Bisson
    Venture Partner
    Teralys Capital Inc.
  • Jean-Paul Castaigne
    Angiochem Inc.
  • Richard Cherney
    Managing Partner
    Davies Ward Phillips & Vineberg, s.r.l.
  • Claude Chevalier
    BIO-K + International Inc.
  • Pierre Falardeau
    Oncozyme Pharma Inc.
  • Jean Godin
    Chief Scientific Officer
    Novartis Pharma Canada Inc.
  • Charles Grubsztajn
    Corporate Director
  • Dr. Pavel Hamet
    Medpharmgene Inc.
  • Grant Perry
    Vice-President, Public Affairs and Reimbursement
    GlaxoSmithKline Inc.
  • Louise Proulx
    Corporate Director


For further information:

Mario Lebrun
General Manager

Profil de l'entreprise


Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.